Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE: Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
NCT07140211Phase 3Recruiting
- Start
- Oct 2025
- Primary completion
- Aug 2030
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of low molecular weight heparin calcium in venous thromboembolism (VTE). Started Oct 2025; status: recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07140211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140211.